Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Assets: 2012-2025

Historic Assets for CorMedix (CRMD) over the last 11 years, with Sep 2025 value amounting to $750.9 million.

  • CorMedix's Assets rose 867.78% to $750.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $750.9 million, marking a year-over-year increase of 867.78%. This contributed to the annual value of $118.8 million for FY2024, which is N/A change from last year.
  • Per CorMedix's latest filing, its Assets stood at $750.9 million for Q3 2025, which was up 197.25% from $252.6 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Assets registered a high of $750.9 million during Q3 2025, and its lowest value of $57.0 million during Q2 2023.
  • For the 3-year period, CorMedix's Assets averaged around $168.3 million, with its median value being $84.5 million (2023).
  • In the last 5 years, CorMedix's Assets fell by 22.94% in 2022 and then surged by 867.78% in 2025.
  • Quarterly analysis of 5 years shows CorMedix's Assets stood at $68.9 million in 2021, then fell by 10.02% to $62.0 million in 2022, then spiked by 47.28% to $91.4 million in 2023, then decreased by 15.14% to $118.8 million in 2024, then spiked by 867.78% to $750.9 million in 2025.
  • Its Assets stands at $750.9 million for Q3 2025, versus $252.6 million for Q2 2025 and $149.6 million for Q1 2025.